Matches in SemOpenAlex for { <https://semopenalex.org/work/W96661483> ?p ?o ?g. }
- W96661483 endingPage "314" @default.
- W96661483 startingPage "299" @default.
- W96661483 abstract "There are approx 8000 new cases of chronic lymphocytic leukemia (CLL) a year in the United States (1). Most patients eventually progress to an advanced stage or develop rapidly progressive disease with a median survival of only 18–36 mo (2). Although allogeneic bone marrow transplantation (including nonmyeloablative conditioning regimens) offers the possibility of longterm remission or cure (3), most patients either lack suitable donors and have comorbidities that prevent such therapy. Monoclonal antibodies, radiolabeled antibody conjugates, and antibody-drug conjugates have been used in CLL and have produced clinical remissions, but most of the responses have been partial and have not been durable. Hence, additional novel agents that may significantly impact on the natural history of this disease are needed. One such class of agents is the immunotoxins consisting of monoclonal antibodies, antibody fragments, or cytokines linked either chemically or genetically to peptide toxins. The antibody or cytokine directs the molecule to the CLL cell surface. The toxin moiety is internalized and translocated to the cytosol, where it enzymatically inactivates protein synthesis inducing programmed cell death. In this review, we discuss the unique biology of the CLL cell that makes it an attractive candidate for immunotoxin therapy. We describe potential CLL cell surface receptors for targeting with immunotoxins as well as the structure and function of selected CLL immunotoxins. Finally, the clinical results of previous and on-going clinical trials with these agents in CLL are analyzed." @default.
- W96661483 created "2016-06-24" @default.
- W96661483 creator A5025737516 @default.
- W96661483 creator A5085248404 @default.
- W96661483 date "2004-01-01" @default.
- W96661483 modified "2023-09-24" @default.
- W96661483 title "Immunotoxin Therapy of Chronic Lymphocytic Leukemia" @default.
- W96661483 cites W1243376384 @default.
- W96661483 cites W125160567 @default.
- W96661483 cites W13898768 @default.
- W96661483 cites W1485481901 @default.
- W96661483 cites W1492263161 @default.
- W96661483 cites W1505424417 @default.
- W96661483 cites W1516227601 @default.
- W96661483 cites W1522536354 @default.
- W96661483 cites W1531578463 @default.
- W96661483 cites W1533598723 @default.
- W96661483 cites W1572544093 @default.
- W96661483 cites W1573890015 @default.
- W96661483 cites W1583749010 @default.
- W96661483 cites W1646540353 @default.
- W96661483 cites W1733558371 @default.
- W96661483 cites W1827071665 @default.
- W96661483 cites W1833241997 @default.
- W96661483 cites W1925857700 @default.
- W96661483 cites W1975521439 @default.
- W96661483 cites W1977898643 @default.
- W96661483 cites W1982836586 @default.
- W96661483 cites W1987149965 @default.
- W96661483 cites W1994154077 @default.
- W96661483 cites W2003081532 @default.
- W96661483 cites W2004023385 @default.
- W96661483 cites W2006140229 @default.
- W96661483 cites W2017784877 @default.
- W96661483 cites W2020031720 @default.
- W96661483 cites W2023864622 @default.
- W96661483 cites W2026623183 @default.
- W96661483 cites W2030419200 @default.
- W96661483 cites W2031224743 @default.
- W96661483 cites W2033384445 @default.
- W96661483 cites W2034500754 @default.
- W96661483 cites W2034637992 @default.
- W96661483 cites W2039981728 @default.
- W96661483 cites W2042890713 @default.
- W96661483 cites W2044556240 @default.
- W96661483 cites W2050120655 @default.
- W96661483 cites W2053541596 @default.
- W96661483 cites W2061365129 @default.
- W96661483 cites W2062634657 @default.
- W96661483 cites W2063192780 @default.
- W96661483 cites W2066388140 @default.
- W96661483 cites W2069219892 @default.
- W96661483 cites W2069301297 @default.
- W96661483 cites W2072767834 @default.
- W96661483 cites W2079756029 @default.
- W96661483 cites W2085611725 @default.
- W96661483 cites W2093455126 @default.
- W96661483 cites W2109110086 @default.
- W96661483 cites W2112628345 @default.
- W96661483 cites W2112997504 @default.
- W96661483 cites W2123927174 @default.
- W96661483 cites W2124835126 @default.
- W96661483 cites W2127961356 @default.
- W96661483 cites W2131510410 @default.
- W96661483 cites W2132433919 @default.
- W96661483 cites W2142645351 @default.
- W96661483 cites W2149628876 @default.
- W96661483 cites W2150235363 @default.
- W96661483 cites W2151735361 @default.
- W96661483 cites W2164860217 @default.
- W96661483 cites W2168750246 @default.
- W96661483 cites W2171634811 @default.
- W96661483 cites W2221262359 @default.
- W96661483 cites W2241314352 @default.
- W96661483 cites W2267215445 @default.
- W96661483 cites W2327389587 @default.
- W96661483 cites W2327436319 @default.
- W96661483 cites W2334647503 @default.
- W96661483 cites W2341863517 @default.
- W96661483 cites W2418073406 @default.
- W96661483 cites W33733012 @default.
- W96661483 cites W4241791800 @default.
- W96661483 cites W4674812 @default.
- W96661483 doi "https://doi.org/10.1007/978-1-59259-412-2_16" @default.
- W96661483 hasPublicationYear "2004" @default.
- W96661483 type Work @default.
- W96661483 sameAs 96661483 @default.
- W96661483 citedByCount "0" @default.
- W96661483 crossrefType "book-chapter" @default.
- W96661483 hasAuthorship W96661483A5025737516 @default.
- W96661483 hasAuthorship W96661483A5085248404 @default.
- W96661483 hasConcept C115085202 @default.
- W96661483 hasConcept C159654299 @default.
- W96661483 hasConcept C203014093 @default.
- W96661483 hasConcept C2777938653 @default.
- W96661483 hasConcept C2778461978 @default.
- W96661483 hasConcept C502942594 @default.
- W96661483 hasConcept C542903549 @default.